Insights

Migraines represent the world’s third most prevalent illness. A new class of drugs called calcitonin gene-related peptide (CGRP) inhibitors entered the market in 2018.

By Angela Maas Republished with Permission from AIS Health Specialty drug trend in 2021 largely recovered from the hit…

Specialty trend maintains double-digit growth as more specialty drugs enter market despite growing prevalence of biosimilars DALLAS, TX (August 23, 2022) – Pharmaceutical Strategies Group (PSG),…

Drug benefit design is increasingly complex. The number of drugs on the market is growing, and decisions about program structure, cost sharing, formulary design,…

When high-deductible health plans (HDHPs) were introduced in the early 2000s, many expected a new era of healthcare consumerism. HDHPs were expected to foster…

Results in PSG’s latest benefit design research reveal an increased focus on member satisfaction DALLAS, Tex. – New research on the latest trends in benefit design launches today.

The latest insights on specialty drug spend and trend across pharmacy and medical benefits The sixth annual State of Specialty Spend and Trend…

At the heart of the investigation: access, pricing, and fair market competition from the six largest vertically integrated pharmacy benefit managers What it is: …

Employers need to strike the right balance when making decisions about specialty drug benefits. So much of the conversation around specialty drugs, understandably, tend…